# OnCo record eganelisib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/eganelisib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "eganelisib" ;
  schema:name "Eganelisib"@en ;
  schema:alternateName "IPI-549"@en ;
  schema:description "Eganelisib is an experimental oral small-molecule kinase inhibitor from Stelexis BioSciences, in phase 2 trials for acute myeloid leukaemia, higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia and other cancers."@en ;
  schema:url <https://onco.cc/drugs/eganelisib/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://stelexis.com/pipeline/>, <https://clinicaltrials.gov/study/NCT06533761>, <https://clinicaltrials.gov/study/NCT07439211>, <https://clinicaltrials.gov/study/NCT03980041>, <https://clinicaltrials.gov/search?intr=eganelisib> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Oral small-molecule kinase inhibitor" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds-higher-risk/>, <https://onco.cc/cancers/cmml/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:targets <https://onco.cc/targets/pik3cg/> ;
  onco:companies <https://onco.cc/companies/stelexis-biosciences/> ;
  onco:trials <https://onco.cc/trials/nct06533761/>, <https://onco.cc/trials/nct07439211/>, <https://onco.cc/trials/nct03980041/>, <https://onco.cc/trials/nct02637531/> .